COLLEGEVILLE, Pa (Thomson Financial) - Wyeth and Belgium-based Solvay Pharmaceuticals Inc said the US Food and Drug Administration has rejected their antipsychotic drug bifeprunox as 'not approvable at this time'.
The companies said in a statement the FDA indicated that a second positive maintenance study could be sufficient to support an application for the drug.
'The companies will meet with the FDA to discuss study design and to assess how this additional study combined with ongoing and planned studies might support a maintenance indication,' they said.
tf.TFN-Europe_newsdesk@thomson.com wj COPYRIGHT Copyright AFX News Limited 2007. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.